News round-up by DDW’s Reece Armstrong for 25-29 April
Q1 earnings, formulations to tackle blindness, liver cancer therapies and opportunities for malaria treatments are some of the themes of this week’s news round-up.
What’s behind GSK’s strong Q1 earnings?
DDW Deputy Editor Reece Armstrong looks at the key points of GSK’s first quarter earnings. UK pharmaceutical company GSK has reported strong financial earnings for the first quarter of 2022. The pharma giant reported total sales in Q1 of £9.8 billion, crediting much of that to the company’s biopharma offerings.
AstraZeneca’s liver cancer therapy gets accepted for review
AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, the company has announced.
World Malaria Day – efforts by the pharma industry
For World Malaria Day DDW looks at some of the latest advancements from the pharmaceutical industry which are helping combat Malaria.
Onyx Scientific expands API offering
Contract development and manufacturing organisation (CDMO) Onyx Scientific has opened a second facility in North East England, expanding its offerings.
New spinout to tackle blindness with novel gel
A new spinout has launched from the University of Birmingham targeting treatments for the leading causes of preventable blindness.
